Design, synthesis, and biological activity of thiazole derivatives as novel influenza neuraminidase inhibitors

References

• Moscona, A. Neuraminidase inhibitors for influenza. N. Engl. J. Med. 2005, 353, 1363–1373.
   PubMed Web of Science ®Google Scholar
• Gong, J., Xu, W., Zhang, J. Structure and functions of influenza virus neuraminidase. Curr. Med. Chem. 2007, 14, 113–122.
   PubMed Web of Science ®Google Scholar
• Chong, A.K., Pegg, M.S., Taylor, N.R., von Itzstein, M. Evidence for a sialosyl cation transition-state complex in the reaction of sialidase from influenza virus. Eur. J. Biochem. 1992, 207, 335–343.
   PubMedGoogle Scholar
• Liu, Y., Zhang, J., Xu, W. Recent progress in rational drug design of neuraminidase inhibitors. Curr. Med. Chem. 2007, 14, 2872–2891.
   PubMed Web of Science ®Google Scholar
• Oxford, J.S., Novelli, P., Sefton, A., Lambkin, R. New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors. Antivir. Chem. Chemother. 2002, 13, 205–217.
   PubMedGoogle Scholar
• Wilson, J.C., von Itzstein, M. Recent strategies in the search for new anti-influenza therapies. Curr. Drug Targets 2003, 4, 389–408.
   PubMed Web of Science ®Google Scholar
• Dreitlein, W.B., Maratos, J., Brocavich, J. Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza. Clin. Ther. 2001, 23, 327–355.
   PubMedGoogle Scholar
• Collins, P.J., Haire, L.F., Lin, Y.P., Liu, J., Russell, R.J., Walker, P.A., Skehel, J.J., Martin, S.R., Hay, A.J., Gamblin, S.J. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature 2008, 453, 1258–1261.
   PubMed Web of Science ®Google Scholar
• Moscona, A. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med. 2009, 360, 953–956.
   PubMed Web of Science ®Google Scholar
• Mihajlovic, M.L., Mitrasinovic, P.M. Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV). Biophys. Chem. 2008, 136, 152–158.
   PubMed Web of Science ®Google Scholar
• Mihajlovic, M.L., Mitrasinovic, P.M. Some novel insights into the binding of oseltamivir and zanamivir to H5N1 and N9 influenza virus neuraminidases: a homology modeling and flexible docking study. J. Serb. Chem. Soc. 2009, 74, 1–13.
   Google Scholar
• Mihajlovic, M.L., Mitrasinovic, P.M. Applications of the ArgusLab4/AScore protocol in the structure-based binding affinity prediction of various inhibitors of group-1 and group-2 influenza virus neuraminidases (NAs). Mol Simulat 2009, 35, 311–324.
   Web of Science ®Google Scholar
• Wang, M.Z., Tai, C.Y., Mendel, D.B. Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir. Antimicrob. Agents Chemother. 2002, 46, 3809–3816.
   PubMed Web of Science ®Google Scholar
• Russell, R.J., Haire, L.F., Stevens, D.J., Collins, P.J., Lin, Y.P., Blackburn, G.M., Hay, A.J., Gamblin, S.J., Skehel, J.J. The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 2006, 443, 45–49.
   PubMed Web of Science ®Google Scholar
• Du, Q.S., Wang, S.Q., Chou, K.C. Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus. Biochem. Biophys. Res. Commun. 2007, 362, 525–531.
   PubMed Web of Science ®Google Scholar
• Mitrasinovic, P.M. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA). Biophys. Chem. 2009, 140, 35–38.
   PubMed Web of Science ®Google Scholar
• Mitrasinovic, P.M. Advances in the structure-based design of the influenza A neuraminidase inhibitors. Curr. Drug Targets 2010, 11, 315–326.
   PubMed Web of Science ®Google Scholar
• Abu Hammad, A.M., Afifi, F.U., Taha, M.O. Combining docking, scoring and molecular field analyses to probe influenza neuraminidase–ligand interactions. J. Mol. Graph. Model. 2007, 26, 443–456.
   PubMed Web of Science ®Google Scholar
• Wang, G.T., Chen, Y., Wang, S., Gentles, R., Sowin, T., Kati, W., Muchmore, S., Giranda, V., Stewart, K., Sham, H., Kempf, D., Laver, W.G. Design, synthesis, and structural analysis of influenza neuraminidase inhibitors containing pyrrolidine cores. J. Med. Chem. 2001, 44, 1192–1201.
   PubMedGoogle Scholar
• Zhang, J., Xu, W. Recent advances in anti-influenza agents with neuraminidase as target. Mini Rev. Med. Chem. 2006, 6, 429–448.
   PubMedGoogle Scholar
• Bossart-Whitaker, P., Carson, M., Babu, Y.S., Smith, C.D., Laver, W.G., Air, G.M. Three-dimensional structure of influenza A N9 neuraminidase and its complex with the inhibitor 2-deoxy 2,3-dehydro-N-acetyl neuraminic acid. J. Mol. Biol. 1993, 232, 1069–1083.
   PubMed Web of Science ®Google Scholar
• Babu, Y.S., Chand, P., Bantia, S., Kotian, P., Dehghani, A., El-Kattan, Y., Lin, T.H., Hutchison, T.L., Elliott, A.J., Parker, C.D., Ananth, S.L., Horn, L.L., Laver, G.W., Montgomery, J.A. BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design. J. Med. Chem. 2000, 43, 3482–3486.
   PubMed Web of Science ®Google Scholar
• Zhang, J., Wang, Q., Fang, H., Xu, W., Liu, A., Du, G. Design, synthesis, inhibitory activity, and SAR studies of pyrrolidine derivatives as neuraminidase inhibitors. Bioorg. Med. Chem. 2007, 15, 2749–2758.
   PubMedGoogle Scholar
• Zhang, J., Wang, Q., Fang, H., Xu, W., Liu, A., Du, G. Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors. Bioorg. Med. Chem. 2008, 16, 3839–3847.
   PubMedGoogle Scholar
• Nielsen, P.E., Haaina, G., Lohse, A., Buchardt, O. Peptide nucleic acids (PNAs) containing thymine monomers derived from chiral amino acids: hybridization and solubility properties of d-lysine PNA. Angew Chem. Int. Ed. Engl. Comm. 1995, 35, 1939–1942.
   Google Scholar
• Lindegårdh, N., Hien, T.T., Farrar, J., Singhasivanon, P., White, N.J., Day, N.P. A simple and rapid liquid chromatographic assay for evaluation of potentially counterfeit Tamiflu. J. Pharm. Biomed. Anal. 2006, 42, 430–433.
   PubMed Web of Science ®Google Scholar
• http://www.nisn.org/documents/Zambon—VIRGIL IC50 SOP.pdf
   Google Scholar
• Wang, T., Wade, R.C. Comparative binding energy (COMBINE) analysis of influenza neuraminidase–inhibitor complexes. J. Med. Chem. 2001, 44, 961–971.
   PubMed Web of Science ®Google Scholar
• Ortiz, A.R., Pisabarro, M.T., Gago, F., Wade, R.C. Prediction of drug binding affinities by comparative binding energy analysis. J. Med. Chem. 1995, 38, 2681–2691.
   PubMed Web of Science ®Google Scholar
• Govorkova, E.A., Leneva, I.A., Goloubeva, O.G., Bush, K., Webster, R.G. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob. Agents Chemother. 2001, 45, 2723–2732.
   PubMed Web of Science ®Google Scholar
• Roberts, N.A., Govorkova, E.A. The activity of neuraminidase inhibitor oseltamivir against all subtypes of influenza viruses. In: Mitrasinovic, P.M., Ed., Global View of the Fight against Influenza. New York: Nova Science Publishers Inc., 2009, pp. 93–118.
   Google Scholar